Overview

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Status:
Completed
Trial end date:
2019-09-12
Target enrollment:
Participant gender:
Summary
Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Pearl Therapeutics, Inc.
Treatments:
Tiotropium Bromide